STUDY TO EVALUATE THE IMPACT OF REACTOGENICITY ON QUALITY OF LIFE (QOL), AFTER ADMINISTRATION OF GLAXOSMITHKLINE (GSK) BIOLOGICALS' CANDIDATE HERPES ZOSTER SUBUNIT (HZ/SU) VACCINE (GSK1437173A) IN ADULTS ≥ 50 YEARS OF AGE: